On August 6, 2021 Sysmex reported that Summary of Consolidated Financial Results [ IFRS ] for the First Three Months of the Fiscal Year Ending March 31, 2022(Press release, Sysmex, AUG 6, 2021, View Source [SID1234586019])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Results for the First Three Months of the Fiscal Year Ending March 31, 2022

(1) Operating results
(2) Financial condition

2. Dividend

3. Financial Forecast for the Year Ending March 31, 20224.
Other Information
(1) Changes in significant consolidated subsidiaries (which resulted in changes in scope of consolidation):
No (2) Changes in accounting policies and accounting estimates
1) Changes in accounting policies required by IFRS:
No 2) Other changes in accounting policies: No 3) Changes in accounting estimates:
No (3) Number of outstanding stock (common stock)

1) Number of outstanding stock at the end of each fiscal period (including treasury stock): 209,458,432 shares as of Jun. 30, 2021; 209,443,232 shares as of Mar. 31, 2021 2) Number of treasury stock at the end of each fiscal period: 446,952 shares as of Jun. 30, 2021; 446,876 shares as of Mar. 31, 2021 3) Average number of outstanding stock for each period (cumulative): 209,003,218 shares for the three months ended Jun. 30, 2021 208,839,381 shares for the three months ended Jun. 30, 2020

Note: Quarterly summaries of financial results are excluded from quarterly reviews. * Explanation regarding the appropriate use of financial forecast and other information

1. Basic earnings per share have been revised from the figures indicated in the consolidated financial forecast announced on May 12, 2021, in accordance with changes in the number of shares of outstanding stock and treasury stock. No other figures in the financial forecast have been revised.
2. The forecasts and future projections contained herein have been prepared on the basis of rational decisions given the information available as of the date of announcement of this document. These forecasts do not represent a commitment by the Company, and actual performance may differ substantially from forecasts for a variety of reasons. Please refer to "3) Consolidated financial forecast" within
"1. Qualitative information on quarterly financial results" on page 4 of the attachment to this document for cautionary statements concerning the conditions and performance forecasts that serve as the basis for these forecasts.
3. Supplementary financial materials (in Japanese and English) will be posted on the Sysmex website on Friday, August 6, 2021.

On August 6, 2021 Philogen reported that it has been invited to the Fall Healthcare Life Sciences & Med Tech Summit organised by Oppenheimer on September 23, 2021 (Press release, Philogen, AUG 6, 2021, View Source [SID1234586009]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The day features virtual presentations and one-on-one meetings with selected emerging companies in the Life Science and MedTech arena. Investors have the opportunity to virtually meet with CEO, CSO Dario Neri to discuss in detail key therapeutic programs in development and any company updates.

On August 6, 2021 Philogen reported its attendance at the Festival of Biologics Basel on November 10, 2021 (Press release, Philogen, AUG 6, 2021, View Source [SID1234586008])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Roberto De Luca, Head of Antibody Therapeutics at Philogen, is giving a lecture entitled "Tripokin: tumor targeted delivery of IL2 potentiated by TNF"

On August 6, 2021 Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, reported that CFO William Duke will participate in a fireside chat at the Canaccord Genuity Growth Conference at 2:30PM ET on Thursday, August 12 (Press release, Kaleido Biosciences, AUG 6, 2021, View Source [SID1234586005]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast of the presentation will be made available in the Investors & Media section of Kaleido’s website at View Source An archived replay will be available for 90 days following the event.

On August 6, 2021 Ichnos Sciences Inc., a global biotechnology company developing innovative biologics in oncology and autoimmune diseases, reported that it has nominated ISB 1442, a CD38 x CD47 bispecific antibody for the treatment of relapsed/refractory multiple myeloma, as its next clinical candidate (Press release, Ichnos Sciences, AUG 6, 2021, View Source [SID1234586004]). This antibody is the first from Ichnos’ proprietary BEAT 2.0 platform1 to advance to preclinical development, and studies are underway to enable the filing of an investigational new drug (IND) application in the first quarter of 2022. With the BEAT 2.0 platform, Ichnos is able to accelerate the design and advancement of novel bi- and trispecific antibodies by optimizing binding affinity, epitope selection, molecular architecture, and Fc (fragment crystallizable) region function.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ISB 1442 is a biparatopic bispecific antibody that combines two proprietary anti-CD38 binding arms, each targeting different regions on CD38, with an antagonistic anti-CD47 arm, making it equivalent to a trispecific antibody. The potency and anti-tumor activity of ISB 1442 has been shown in multiple in vitro and in vivo models. Additionally, the ability of ISB 1442 to simultaneously bind to CD38 and block CD47, and its enhanced signaling of FcR (fragment crystallizable receptors) on immune cells, differentiate it from anti-CD38 monospecific targeting therapeutics.

"Ichnos continues to make progress with this novel bispecific approach co-targeting CD38 and CD47 in hematologic malignancies, and we plan to share ISB 1442 preclinical results at a scientific congress later this year," said Cyril Konto, M.D., Chief Executive Officer of Ichnos. "We expect to initiate the first-in-human clinical study in relapsed/refractory multiple myeloma patients in the middle of next year. Despite having numerous products approved for this disease, patients continue to relapse, and more effective therapies are needed. Based on its unique design and mechanism of action, ISB 1442 is anticipated to enhance anti-tumor activity relative to anti-CD38 targeted therapies by overcoming primary and acquired tumor mechanisms of resistance."